Arrowhead Pharmaceuticals...

11.24
-0.11 (-0.97%)
At close: Apr 17, 2025, 3:59 PM
-0.97%
Bid 10.82
Market Cap 1.54B
Revenue (ttm) 2.5M
Net Income (ttm) -639.71M
EPS (ttm) -5.15
PE Ratio (ttm) -2.18
Forward PE -3.06
Analyst Buy
Ask 13
Volume 2,367,656
Avg. Volume (20D) 2,103,609
Open 11.27
Previous Close 11.35
Day's Range 10.93 - 11.50
52-Week Range 9.57 - 30.41
Beta 1.00

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 1993
Employees 609
Stock Exchange NASDAQ
Ticker Symbol ARWR
Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $34.5, which is an increase of 206.94% from the latest price.

Stock Forecasts

Next Earnings Release

Arrowhead Pharmaceuticals Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-10.37%
Arrowhead Pharmaceuticals shares are trading lower... Unlock content with Pro Subscription
2 months ago
-5.17%
Arrowhead Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results.